dm+d

40820003

Articles

Example medicines to prescribe by brand name in primary care

27 March 2022Prescribe certain medicines by brand to ensure supply of the same product. Examples are grouped by therapeutic area. The list of products is not exhaustive.

Switching between liquid and tablet/capsule formulations - Which medicines require extra care?

19 July 2021For a small number of medicines, there are differences in equivalent doses of oral formulations of the same medicine. This needs to be considered when…

How should medicines be dosed in children who are obese?

28 May 2021Review on how to calculate medicine doses in children who are obese which includes a table on commonly prescribed medicines.

Safety in Lactation: Drugs for bipolar disorder and hypomania

21 October 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Whilst valproate (valproic acid/sodium valproate) is…
Search Articles

Medicine Compliance Aid Stability

TegretolNovartis Pharmaceuticals UK Ltd

Novartis Pharmaceuticals UK Ltd
Tegretol
Tablets 100mg, 200mg, 400mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from moisture
Protect from moisture and maximum of 8 days in MCA. Store in airtight container.
9 February 2015

Tegretol prolonged releaseNovartis Pharmaceuticals UK Ltd

Novartis Pharmaceuticals UK Ltd
Tegretol prolonged release
Tablets m/r 200mg, 400mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from moisture
Protect from moisture and maximum of 8 days in MCA. Store in airtight container.
9 February 2015

TegretolNovartis Pharmaceuticals UK Ltd

Novartis Pharmaceuticals UK Ltd
Tegretol
Chewtabs 100mg, 200mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from moisture
Protect from moisture and maximum of 8 days in MCA. Store in airtight container.
9 February 2015

genericNon-proprietary

Non-proprietary
generic
Tablets 100mg, 200mg, 400mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from moisture
Protect from moisture and maximum of 8 days in MCA. Store in airtight container.
9 February 2015

Carbagen SRGenerics UK Ltd

Generics UK Ltd
Carbagen SR
Tablets f/c m/r 200mg, 400mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from moisture
Protect from moisture and maximum of 8 days in MCA. Store in airtight container.
9 February 2015

Lactation Safety Information

For bipolar disorder

For bipolar disorder
Appropriate second generation antipsychotic
Significant published evidence of use in breastfeeding
Significant amounts in breast milk
Case reports of sedation, poor suckling, withdrawal reactions, and hepatic dysfunction reported in infants exposed to carbamazepine via breast milk
Monitor infant for signs of sedation, poor feeding ad liver dysfunction
3 January 2018

Oral / Rectal For epilepsy

Oral / Rectal
For epilepsy
Suitable alternative antiepileptic
Significant published evidence of use in breastfeeding
Relatively high, but subtherapeutic, amounts in breast milk
Case reports of sedation, poor suckling, regurgitation with vomiting, withdrawal reactions, and hepatic dysfunction in infants exposed to carbamazepine via breast milk
Monitor infant for GI symptoms and signs of liver dysfunction
18 September 2018